organization · Reporting owner

GV 2017, L.P.

Disclosed activity across 5 companies

Tapewire entity: 11121
SEC CIK: 0001733340

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Arcus Biosciences, Inc.RCUS · Entity 4104	10% owner	March 19, 2018	March 19, 2018
Ethos Technologies Inc.LIFE · Entity 4157	10% owner	January 30, 2026	January 30, 2026
Gitlab Inc.GTLB · Entity 3663	10% owner	October 18, 2021	May 06, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arcus Biosciences, Inc.

Report date March 19, 2018 · Filed March 19, 2018

Jointly reported with GV 2017 GP, L.L.C., GV 2017 GP, L.P., Alphabet Inc.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy GV 2017, L.P.	1,924,474	Reported balance After 2018-03-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-03-19 · Conversion · Acquired 1,924,474 · Balance 1,924,474 F1: The total represents shares received upon conversion of shares of Series C Convertible Preferred Stock. F3: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2: The reported security is directly held by GV 2017, L.P. GV 2017 GP, L.P., the general partner of GV 2017, L.P., GV 2017 GP, L.L.C., the general partner of GV 2017 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2017 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Each of GV 2017 GP, L.P., GV 2017 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc. and Alphabet Inc. disclaim beneficial ownership of the shares except to the extent of any pecuniary interest therein.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy GV 2017, L.P.	0	Reported balance After 2018-03-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-19 · Conversion · Disposed 1,924,474 · Balance 0 F3: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2: The reported security is directly held by GV 2017, L.P. GV 2017 GP, L.P., the general partner of GV 2017, L.P., GV 2017 GP, L.L.C., the general partner of GV 2017 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2017 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Each of GV 2017 GP, L.P., GV 2017 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc. and Alphabet Inc. disclaim beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The total represents shares received upon conversion of shares of Series C Convertible Preferred Stock.

F2: The reported security is directly held by GV 2017, L.P. GV 2017 GP, L.P., the general partner of GV 2017, L.P., GV 2017 GP, L.L.C., the general partner of GV 2017 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2017 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Each of GV 2017 GP, L.P., GV 2017 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc. and Alphabet Inc. disclaim beneficial ownership of the shares except to the extent of any pecuniary interest therein.

F3: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Ethos Technologies Inc.

Report date January 30, 2026 · Filed January 30, 2026

Jointly reported with GV 2017 GP, L.L.C., GV 2017 GP, L.P., GV 2019 GP, L.L.C., GV 2019 GP, L.P., GV 2019, L.P., GV 2021 GP, L.L.C., GV 2021 GP, L.P., GV 2021, L.P., Alphabet Inc.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectBy GV 2017, L.P.	0	Last balance in matching sequence After 2026-01-30 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-01-30 · Conversion · Acquired 1,755,632 · Balance 1,755,632 F1: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F2: The securities reported in this row are directly beneficially owned by GV 2017, L.P. (the "2017 Partnership"). GV 2017 GP, L.P. (the "2017 GP") is the general partner of the 2017 Partnership. GV 2017 GP, L.L.C. ("GV 2017 LLC") is the general partner of the 2017 GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2017 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) the securities directly beneficially owned by the 2017 Partnership. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Row 4 · 2026-01-30 · Sale · Disposed 1,755,632 · Balance 0 F5: The reported transaction represents a sale of shares of the Issuer's Class A Common Stock by the reporting person as a participant in a secondary offering undertaken in connection with the Issuer's underwritten initial public offering of its Class A Common Stock. F2: The securities reported in this row are directly beneficially owned by GV 2017, L.P. (the "2017 Partnership"). GV 2017 GP, L.P. (the "2017 GP") is the general partner of the 2017 Partnership. GV 2017 GP, L.L.C. ("GV 2017 LLC") is the general partner of the 2017 GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2017 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) the securities directly beneficially owned by the 2017 Partnership. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Class A Common StockSEC Table I · non-derivative	IndirectBy GV 2019, L.P.	3,198,249	Last balance in matching sequence After 2026-01-30 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 2 · 2026-01-30 · Conversion · Acquired 3,287,925 · Balance 3,287,925 F1: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F3: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Row 5 · 2026-01-30 · Sale · Disposed 89,676 · Balance 3,198,249 F5: The reported transaction represents a sale of shares of the Issuer's Class A Common Stock by the reporting person as a participant in a secondary offering undertaken in connection with the Issuer's underwritten initial public offering of its Class A Common Stock. F3: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Class A Common StockSEC Table I · non-derivative	IndirectBy GV 2021, L.P.	571,907	Reported balance After 2026-01-30 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-01-30 · Conversion · Acquired 571,907 · Balance 571,907 F1: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F4: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). GV 2021 GP, L.P. (the "2021 GP") is the general partner of the 2021 Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the 2021 GP. Alphabet Holdings is the sole member of GV 2021 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2021 Partnership. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy GV 2017, L.P.	0	Reported balance After 2026-01-30 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-01-30 · Conversion · Disposed 1,751,791 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F2: The securities reported in this row are directly beneficially owned by GV 2017, L.P. (the "2017 Partnership"). GV 2017 GP, L.P. (the "2017 GP") is the general partner of the 2017 Partnership. GV 2017 GP, L.L.C. ("GV 2017 LLC") is the general partner of the 2017 GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2017 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) the securities directly beneficially owned by the 2017 Partnership. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectBy GV 2019, L.P.	0	Reported balance After 2026-01-30 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-30 · Conversion · Disposed 3,287,925 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F3: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series D Preferred StockSEC Table II · derivative / convertible security	IndirectBy GV 2021, L.P.	0	Reported balance After 2026-01-30 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-01-30 · Conversion · Disposed 552,126 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F4: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). GV 2021 GP, L.P. (the "2021 GP") is the general partner of the 2021 Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the 2021 GP. Alphabet Holdings is the sole member of GV 2021 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2021 Partnership. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation.

F2: The securities reported in this row are directly beneficially owned by GV 2017, L.P. (the "2017 Partnership"). GV 2017 GP, L.P. (the "2017 GP") is the general partner of the 2017 Partnership. GV 2017 GP, L.L.C. ("GV 2017 LLC") is the general partner of the 2017 GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2017 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) the securities directly beneficially owned by the 2017 Partnership. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F3: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F4: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). GV 2021 GP, L.P. (the "2021 GP") is the general partner of the 2021 Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the 2021 GP. Alphabet Holdings is the sole member of GV 2021 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2021 Partnership. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F5: The reported transaction represents a sale of shares of the Issuer's Class A Common Stock by the reporting person as a participant in a secondary offering undertaken in connection with the Issuer's underwritten initial public offering of its Class A Common Stock.

Gitlab Inc.

Report date October 18, 2021 · Filed May 06, 2022

Jointly reported with GV 2017 GP, L.L.C., GV 2017 GP, L.P., Alphabet Inc.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Common StockSEC Table II · derivative / convertible security	IndirectBy GV 2017, L.P.	8,888,776	Reported balance After 2021-10-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-10-18 · Conversion · Acquired 8,888,776 · Balance 8,888,776 F1: Each share of Class B Common Stock is convertible into one share of the Issuer's Class A Common Stock at any time and will convert automatically upon certain transfers, whether or not for value, as well as upon the earliest of: (i) the tenth anniversary of the date of the Issuer's initial public offering (the "IPO"); (ii) the death or disability of Sytse Sijbrandij; (iii) the first date following the completion of the IPO on which the number of shares of outstanding Class B Common Stock (including shares of Class B Common Stock subject to outstanding stock options) is less than 5% of the aggregate number of shares of the Issuer's common stock of all classes then outstanding; and (iv) the date specified by a vote of the holders of two-thirds of the then outstanding shares of Class B Common Stock. F2: The securities reported in this row are held directly held by GV 2017, L.P. (the "Partnership"). The general partner of the Partnership is GV 2017 GP, L.P. (the "GP"). The general partner of the GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole managing member of GV 2017 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole managing member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectBy GV 2017, L.P.	0	Reported balance After 2021-10-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-10-18 · Conversion · Disposed 8,374,040 · Balance 0 F3: Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one share of Class B Common Stock immediately prior to the closing of the IPO. Other than the aforementioned conversion, Series B Preferred Stock and Series C Preferred Stock have no expiration date. F2: The securities reported in this row are held directly held by GV 2017, L.P. (the "Partnership"). The general partner of the Partnership is GV 2017 GP, L.P. (the "GP"). The general partner of the GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole managing member of GV 2017 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole managing member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series D Preferred StockSEC Table II · derivative / convertible security	IndirectBy GV 2017, L.P.	0	Reported balance After 2021-10-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-10-18 · Conversion · Disposed 514,736 · Balance 0 F3: Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one share of Class B Common Stock immediately prior to the closing of the IPO. Other than the aforementioned conversion, Series B Preferred Stock and Series C Preferred Stock have no expiration date. F2: The securities reported in this row are held directly held by GV 2017, L.P. (the "Partnership"). The general partner of the Partnership is GV 2017 GP, L.P. (the "GP"). The general partner of the GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole managing member of GV 2017 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole managing member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Class B Common Stock is convertible into one share of the Issuer's Class A Common Stock at any time and will convert automatically upon certain transfers, whether or not for value, as well as upon the earliest of: (i) the tenth anniversary of the date of the Issuer's initial public offering (the "IPO"); (ii) the death or disability of Sytse Sijbrandij; (iii) the first date following the completion of the IPO on which the number of shares of outstanding Class B Common Stock (including shares of Class B Common Stock subject to outstanding stock options) is less than 5% of the aggregate number of shares of the Issuer's common stock of all classes then outstanding; and (iv) the date specified by a vote of the holders of two-thirds of the then outstanding shares of Class B Common Stock.

F2: The securities reported in this row are held directly held by GV 2017, L.P. (the "Partnership"). The general partner of the Partnership is GV 2017 GP, L.P. (the "GP"). The general partner of the GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole managing member of GV 2017 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole managing member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F3: Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one share of Class B Common Stock immediately prior to the closing of the IPO. Other than the aforementioned conversion, Series B Preferred Stock and Series C Preferred Stock have no expiration date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Decibel Therapeutics, Inc.

Report date February 17, 2021 · Filed February 17, 2021

Jointly reported with GV 2017 GP, L.L.C., GV 2017 GP, L.P.

Section 16 reporting ended · disclosed 2021-02-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy GV 2017, L.P.	494,649	Reported balance After 2021-02-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-02-17 · Conversion · Acquired 494,649 · Balance 494,649 F1: The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value per share, on an approximately 12.635:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F2: The reported securities are held directly by GV 2017, L.P. GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2017 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Each of GV 2017 GP, L.P., GV 2017 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc. disclaim beneficial ownership of the shares except to the extent of any pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectBy GV 2017, L.P.	0	Reported balance After 2021-02-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-02-17 · Conversion · Disposed 6,250,000 · Balance 0 F1: The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value per share, on an approximately 12.635:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F2: The reported securities are held directly by GV 2017, L.P. GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2017 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Each of GV 2017 GP, L.P., GV 2017 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc. disclaim beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value per share, on an approximately 12.635:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date.

F2: The reported securities are held directly by GV 2017, L.P. GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2017 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Each of GV 2017 GP, L.P., GV 2017 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc. disclaim beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Verve Therapeutics, Inc.

Report date July 25, 2025 · Filed July 28, 2025

Jointly reported with GV 2017 GP, L.L.C., GV 2017 GP, L.P., GV 2019 GP, L.L.C., GV 2019 GP, L.P., GV 2019, L.P., GV 2023 GP, L.L.C., GV 2023 GP, L.P., GV 2023, L.P., Alphabet Inc.

Section 16 reporting ended · disclosed 2025-07-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy GV 2017 L.P.	Reported balance After 2025-07-25 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-07-25 · Other · Disposed 6,108,442 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock (the "Common Stock"). In exchange for each share, tendering stockholders received: (i) $10.50 per share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR" and, together with the Cash Consideration, the "Offer Price"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business, F2: (continued from footnote 1) in accordance with the terms and subject to the conditions and other provisions of a contingent value rights agreement entered into by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and an indirect wholly owned subsidiary of Parent. F3: The securities reported in this row are directly held by GV 2017, L.P. (the "2017 Partnership"). The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the "2017 GP"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole member of GV 2017 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy GV 2019 L.P.	Reported balance After 2025-07-25 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-07-25 · Other · Disposed 4,260,047 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock (the "Common Stock"). In exchange for each share, tendering stockholders received: (i) $10.50 per share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR" and, together with the Cash Consideration, the "Offer Price"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business, F2: (continued from footnote 1) in accordance with the terms and subject to the conditions and other provisions of a contingent value rights agreement entered into by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and an indirect wholly owned subsidiary of Parent. F4: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy GV 2023, L.P.	Reported balance After 2025-07-25 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-07-25 · Other · Disposed 1,800,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock (the "Common Stock"). In exchange for each share, tendering stockholders received: (i) $10.50 per share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR" and, together with the Cash Consideration, the "Offer Price"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business, F2: (continued from footnote 1) in accordance with the terms and subject to the conditions and other provisions of a contingent value rights agreement entered into by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and an indirect wholly owned subsidiary of Parent. F5: The securities reported in this row are directly beneficially owned by GV 2023, L.P. (the "2023 Partnership"). GV 2023 GP, L.P. (the "2023 GP") is the general partner of the 2023 Partnership. GV 2023 GP, L.L.C. ("GV 2023 LLC") is the general partner of the 2023 GP. Alphabet Holdings is the sole member of GV 2023 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2023 Partnership. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock (the "Common Stock"). In exchange for each share, tendering stockholders received: (i) $10.50 per share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR" and, together with the Cash Consideration, the "Offer Price"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business,

F2: (continued from footnote 1) in accordance with the terms and subject to the conditions and other provisions of a contingent value rights agreement entered into by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and an indirect wholly owned subsidiary of Parent.

F3: The securities reported in this row are directly held by GV 2017, L.P. (the "2017 Partnership"). The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the "2017 GP"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole member of GV 2017 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F4: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F5: The securities reported in this row are directly beneficially owned by GV 2023, L.P. (the "2023 Partnership"). GV 2023 GP, L.P. (the "2023 GP") is the general partner of the 2023 Partnership. GV 2023 GP, L.L.C. ("GV 2023 LLC") is the general partner of the 2023 GP. Alphabet Holdings is the sole member of GV 2023 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2023 Partnership. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 30, 2026 Filed Jan 30, 2026 23:43 UTC	Ethos Technologies Inc. LIFE · Entity 4157	ConversionSeries D Preferred Stock · Derivative	552,126	Not disclosed	Not disclosed	Disclosure SEC source: 0001168404-26-000007 · form4-01302026_110152.xml · derivative · entry 8 GV 2017 GP, L.L.C. · CIK 0001733338 · 10% owner GV 2017 GP, L.P. · CIK 0001733339 · 10% owner GV 2017, L.P. · CIK 0001733340 · 10% owner GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2021, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 571,907 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F4 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). GV 2021 GP, L.P. (the "2021 GP") is the general partner of the 2021 Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the 2021 GP. Alphabet Holdings is the sole member of GV 2021 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2021 Partnership. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
January 30, 2026 Filed Jan 30, 2026 23:43 UTC	Ethos Technologies Inc. LIFE · Entity 4157	ConversionSeries C Preferred Stock · Derivative	3,287,925	Not disclosed	Not disclosed	Disclosure SEC source: 0001168404-26-000007 · form4-01302026_110152.xml · derivative · entry 7 GV 2017 GP, L.L.C. · CIK 0001733338 · 10% owner GV 2017 GP, L.P. · CIK 0001733339 · 10% owner GV 2017, L.P. · CIK 0001733340 · 10% owner GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 3,287,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
January 30, 2026 Filed Jan 30, 2026 23:43 UTC	Ethos Technologies Inc. LIFE · Entity 4157	ConversionSeries B Preferred Stock · Derivative	1,751,791	Not disclosed	Not disclosed	Disclosure SEC source: 0001168404-26-000007 · form4-01302026_110152.xml · derivative · entry 6 GV 2017 GP, L.L.C. · CIK 0001733338 · 10% owner GV 2017 GP, L.P. · CIK 0001733339 · 10% owner GV 2017, L.P. · CIK 0001733340 · 10% owner GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2017, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 1,755,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2017, L.P. (the "2017 Partnership"). GV 2017 GP, L.P. (the "2017 GP") is the general partner of the 2017 Partnership. GV 2017 GP, L.L.C. ("GV 2017 LLC") is the general partner of the 2017 GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2017 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) the securities directly beneficially owned by the 2017 Partnership. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
January 30, 2026 Filed Jan 30, 2026 23:43 UTC	Ethos Technologies Inc. LIFE · Entity 4157	SaleClass A Common Stock	89,676	$19.00	$1,703,844.00	Disclosure SEC source: 0001168404-26-000007 · form4-01302026_110152.xml · nonDerivative · entry 5 GV 2017 GP, L.L.C. · CIK 0001733338 · 10% owner GV 2017 GP, L.P. · CIK 0001733339 · 10% owner GV 2017, L.P. · CIK 0001733340 · 10% owner GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 3,198,249 F5 · kind: The reported transaction represents a sale of shares of the Issuer's Class A Common Stock by the reporting person as a participant in a secondary offering undertaken in connection with the Issuer's underwritten initial public offering of its Class A Common Stock. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
January 30, 2026 Filed Jan 30, 2026 23:43 UTC	Ethos Technologies Inc. LIFE · Entity 4157	SaleClass A Common Stock	1,755,632	$19.00	$33,357,008.00	Disclosure SEC source: 0001168404-26-000007 · form4-01302026_110152.xml · nonDerivative · entry 4 GV 2017 GP, L.L.C. · CIK 0001733338 · 10% owner GV 2017 GP, L.P. · CIK 0001733339 · 10% owner GV 2017, L.P. · CIK 0001733340 · 10% owner GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2017, L.P. Disclosed balance after: 0 F5 · kind: The reported transaction represents a sale of shares of the Issuer's Class A Common Stock by the reporting person as a participant in a secondary offering undertaken in connection with the Issuer's underwritten initial public offering of its Class A Common Stock. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2017, L.P. (the "2017 Partnership"). GV 2017 GP, L.P. (the "2017 GP") is the general partner of the 2017 Partnership. GV 2017 GP, L.L.C. ("GV 2017 LLC") is the general partner of the 2017 GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2017 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) the securities directly beneficially owned by the 2017 Partnership. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
January 30, 2026 Filed Jan 30, 2026 23:43 UTC	Ethos Technologies Inc. LIFE · Entity 4157	ConversionClass A Common Stock	571,907	Not disclosed	Not disclosed	Disclosure SEC source: 0001168404-26-000007 · form4-01302026_110152.xml · nonDerivative · entry 3 GV 2017 GP, L.L.C. · CIK 0001733338 · 10% owner GV 2017 GP, L.P. · CIK 0001733339 · 10% owner GV 2017, L.P. · CIK 0001733340 · 10% owner GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2021, L.P. Disclosed balance after: 571,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F4 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). GV 2021 GP, L.P. (the "2021 GP") is the general partner of the 2021 Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the 2021 GP. Alphabet Holdings is the sole member of GV 2021 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2021 Partnership. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
January 30, 2026 Filed Jan 30, 2026 23:43 UTC	Ethos Technologies Inc. LIFE · Entity 4157	ConversionClass A Common Stock	3,287,925	Not disclosed	Not disclosed	Disclosure SEC source: 0001168404-26-000007 · form4-01302026_110152.xml · nonDerivative · entry 2 GV 2017 GP, L.L.C. · CIK 0001733338 · 10% owner GV 2017 GP, L.P. · CIK 0001733339 · 10% owner GV 2017, L.P. · CIK 0001733340 · 10% owner GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 3,287,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
January 30, 2026 Filed Jan 30, 2026 23:43 UTC	Ethos Technologies Inc. LIFE · Entity 4157	ConversionClass A Common Stock	1,755,632	Not disclosed	Not disclosed	Disclosure SEC source: 0001168404-26-000007 · form4-01302026_110152.xml · nonDerivative · entry 1 GV 2017 GP, L.L.C. · CIK 0001733338 · 10% owner GV 2017 GP, L.P. · CIK 0001733339 · 10% owner GV 2017, L.P. · CIK 0001733340 · 10% owner GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2017, L.P. Disclosed balance after: 1,755,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B, Series C, and Series D Preferred Stock were automatically converted into shares of Class A Common Stock of the Issuer pursuant to the Issuer's Amended and Restated Certificate of Incorporation. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2017, L.P. (the "2017 Partnership"). GV 2017 GP, L.P. (the "2017 GP") is the general partner of the 2017 Partnership. GV 2017 GP, L.L.C. ("GV 2017 LLC") is the general partner of the 2017 GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2017 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) the securities directly beneficially owned by the 2017 Partnership. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
July 25, 2025 Filed Jul 28, 2025 17:19 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	OtherCommon Stock	1,800,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-020384 · form4-07282025_090715.xml · nonDerivative · entry 3 GV 2017 GP, L.L.C. · CIK 0001733338 · 10% owner GV 2017 GP, L.P. · CIK 0001733339 · 10% owner GV 2017, L.P. · CIK 0001733340 · 10% owner GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2023 GP, L.L.C. · CIK 0001961991 · 10% owner GV 2023 GP, L.P. · CIK 0001961990 · 10% owner GV 2023, L.P. · CIK 0001961979 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2023, L.P. Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock (the "Common Stock"). In exchange for each share, tendering stockholders received: (i) $10.50 per share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR" and, together with the Cash Consideration, the "Offer Price"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business, F2 · price: (continued from footnote 1) in accordance with the terms and subject to the conditions and other provisions of a contingent value rights agreement entered into by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and an indirect wholly owned subsidiary of Parent. F5 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2023, L.P. (the "2023 Partnership"). GV 2023 GP, L.P. (the "2023 GP") is the general partner of the 2023 Partnership. GV 2023 GP, L.L.C. ("GV 2023 LLC") is the general partner of the 2023 GP. Alphabet Holdings is the sole member of GV 2023 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2023 Partnership. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
July 25, 2025 Filed Jul 28, 2025 17:19 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	OtherCommon Stock	4,260,047	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-020384 · form4-07282025_090715.xml · nonDerivative · entry 2 GV 2017 GP, L.L.C. · CIK 0001733338 · 10% owner GV 2017 GP, L.P. · CIK 0001733339 · 10% owner GV 2017, L.P. · CIK 0001733340 · 10% owner GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2023 GP, L.L.C. · CIK 0001961991 · 10% owner GV 2023 GP, L.P. · CIK 0001961990 · 10% owner GV 2023, L.P. · CIK 0001961979 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock (the "Common Stock"). In exchange for each share, tendering stockholders received: (i) $10.50 per share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR" and, together with the Cash Consideration, the "Offer Price"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business, F2 · price: (continued from footnote 1) in accordance with the terms and subject to the conditions and other provisions of a contingent value rights agreement entered into by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and an indirect wholly owned subsidiary of Parent. F4 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
July 25, 2025 Filed Jul 28, 2025 17:19 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	OtherCommon Stock	6,108,442	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-020384 · form4-07282025_090715.xml · nonDerivative · entry 1 GV 2017 GP, L.L.C. · CIK 0001733338 · 10% owner GV 2017 GP, L.P. · CIK 0001733339 · 10% owner GV 2017, L.P. · CIK 0001733340 · 10% owner GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2023 GP, L.L.C. · CIK 0001961991 · 10% owner GV 2023 GP, L.P. · CIK 0001961990 · 10% owner GV 2023, L.P. · CIK 0001961979 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2017 L.P. Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock (the "Common Stock"). In exchange for each share, tendering stockholders received: (i) $10.50 per share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR" and, together with the Cash Consideration, the "Offer Price"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business, F2 · price: (continued from footnote 1) in accordance with the terms and subject to the conditions and other provisions of a contingent value rights agreement entered into by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and an indirect wholly owned subsidiary of Parent. F3 · ownership.nature: The securities reported in this row are directly held by GV 2017, L.P. (the "2017 Partnership"). The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the "2017 GP"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole member of GV 2017 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	243	$32.90	$7,994.70	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 7 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,260,047 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F7 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	650	$31.99	$20,793.83	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 6 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,260,290 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 to $32.20, inclusive. F7 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	47,690	$31.12	$1,484,017.42	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 5 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,260,940 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.51 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F7 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	242	$32.90	$7,961.80	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 4 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	651	$31.99	$20,825.82	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 3 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 242 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 to $32.20, inclusive. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	47,690	$31.12	$1,484,017.42	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 2 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 893 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.51 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	OtherCommon Stock	48,583	$0.00	$0.00	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 1 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2017 L.P. Disclosed balance after: 6,108,442 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by GV 2017, L.P. (the "2017 Partnership") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2017 Partnership's affiliate, Alphabet Holdings LLC ("Alphabet Holdings"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: The securities reported in this row are directly held by the 2017 Partnership. The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the "2017 GP"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole managing member of GV 2017 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 03, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	1,755	$33.84	$59,384.46	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 14 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,308,630 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.62 to $34.27, inclusive. F8 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 03, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	25,534	$33.14	$846,155.91	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 13 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,310,385 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.62 to $33.61, inclusive. F8 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 03, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	22,279	$32.32	$719,957.02	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 12 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,335,919 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.62 to $32.61, inclusive. F8 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 03, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	1,755	$33.84	$59,384.46	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 11 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.62 to $34.27, inclusive. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 03, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	25,535	$33.14	$846,189.04	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 10 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 1,755 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.62 to $33.61, inclusive. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 03, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	22,279	$32.32	$719,957.02	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 9 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 27,290 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.62 to $32.61, inclusive. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 03, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	OtherCommon Stock	49,569	$0.00	$0.00	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 8 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2017 L.P. Disclosed balance after: 6,157,025 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by GV 2017, L.P. (the "2017 Partnership") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2017 Partnership's affiliate, Alphabet Holdings LLC ("Alphabet Holdings"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: The securities reported in this row are directly held by the 2017 Partnership. The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the "2017 GP"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole managing member of GV 2017 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 02, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	8,930	$36.78	$328,400.75	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 7 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,358,198 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.60 to $37.03, inclusive. F8 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 02, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	10,372	$36.28	$376,281.64	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 6 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,367,128 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.60 to $36.595, inclusive. F8 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 02, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	9,350	$34.78	$325,149.99	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 5 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,377,500 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.56 to $35.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnotes 6 and 7 and 9 through 11 of this Form 4. F8 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 02, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	8,930	$36.78	$328,400.75	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 4 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.60 to $37.03, inclusive. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 02, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	10,372	$36.28	$376,281.64	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 3 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 8,930 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.60 to $36.595, inclusive. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 02, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	9,349	$34.78	$325,115.21	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 2 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 19,302 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.56 to $35.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnotes 6 and 7 and 9 through 11 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 02, 2022 Filed Nov 4, 2022 16:16 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	OtherCommon Stock	28,651	$0.00	$0.00	Disclosure SEC source: 0001209191-22-055791 · doc4.xml · nonDerivative · entry 1 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2017 L.P. Disclosed balance after: 6,206,594 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by GV 2017, L.P. (the "2017 Partnership") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2017 Partnership's affiliate, Alphabet Holdings LLC ("Alphabet Holdings"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: The securities reported in this row are directly held by the 2017 Partnership. The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the "2017 GP"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole managing member of GV 2017 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 01, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	260	$38.64	$10,046.01	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 16 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,386,850 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.59 to $38.65, inclusive. F9 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 01, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	2,377	$37.82	$89,900.52	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 15 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,387,110 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.35 to $38.30, inclusive. F9 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 01, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	29,326	$36.69	$1,075,906.42	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 14 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,389,487 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.34 to $37.33, inclusive. F9 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 01, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	260	$38.64	$10,046.01	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 13 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.59 to $38.65, inclusive. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 01, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	2,377	$37.82	$89,900.52	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 12 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 260 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.35 to $38.30, inclusive. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 01, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	29,326	$36.69	$1,075,906.42	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 11 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 2,637 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.34 to $37.33, inclusive. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 01, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	OtherCommon Stock	31,963	$0.00	$0.00	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 10 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2017 L.P. Disclosed balance after: 6,235,245 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by GV 2017, L.P. (the "2017 Partnership") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2017 Partnership's affiliate, Alphabet Holdings LLC ("Alphabet Holdings"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: The securities reported in this row are directly held by the 2017 Partnership. The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the "2017 GP"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole managing member of GV 2017 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
October 31, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	88	$40.64	$3,576.72	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 9 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,418,813 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.61 to $40.69, inclusive. F9 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
October 31, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	6,601	$40.16	$265,075.70	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 8 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,418,901 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.6198 to $40.42, inclusive. F9 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
October 31, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	23,275	$38.94	$906,402.98	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 7 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,425,502 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $39.5858, inclusive. F9 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
October 31, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	23,732	$37.91	$899,587.57	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 6 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,448,777 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $38.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnotes 6 through 8 and 10 through 12 of this Form 4. F9 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
October 31, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	88	$40.64	$3,576.72	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 5 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.61 to $40.69, inclusive. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
October 31, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	6,601	$40.16	$265,075.70	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 4 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 88 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.6198 to $40.42, inclusive. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
October 31, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	23,276	$38.94	$906,441.92	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 3 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 6,689 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $39.5858, inclusive. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
October 31, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	23,732	$37.91	$899,587.57	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 2 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 29,965 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $38.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnotes 6 through 8 and 10 through 12 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
October 31, 2022 Filed Nov 2, 2022 16:25 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	OtherCommon Stock	53,697	$0.00	$0.00	Disclosure SEC source: 0001209191-22-055288 · doc4.xml · nonDerivative · entry 1 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2017 L.P. Disclosed balance after: 6,267,208 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by GV 2017, L.P. (the "2017 Partnership") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2017 Partnership's affiliate, Alphabet Holdings LLC ("Alphabet Holdings"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: The securities reported in this row are directly held by the 2017 Partnership. The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the "2017 GP"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole managing member of GV 2017 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
October 18, 2021 Filed May 6, 2022 16:18 UTC	Gitlab Inc. GTLB · Entity 3663	ConversionSeries D Preferred Stock · Derivative	514,736	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-027590 · doc4.xml · derivative · entry 3 GV 2017 GP, L.L.C. · CIK 0001733338 · 10% owner GV 2017 GP, L.P. · CIK 0001733339 · 10% owner GV 2017, L.P. · CIK 0001733340 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2017, L.P. Disclosed balance after: 0 Underlying: Class B Common Stock · 514,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one share of Class B Common Stock immediately prior to the closing of the IPO. Other than the aforementioned conversion, Series B Preferred Stock and Series C Preferred Stock have no expiration date. F3 · price: Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one share of Class B Common Stock immediately prior to the closing of the IPO. Other than the aforementioned conversion, Series B Preferred Stock and Series C Preferred Stock have no expiration date. F3 · derivative.exercise_date: Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one share of Class B Common Stock immediately prior to the closing of the IPO. Other than the aforementioned conversion, Series B Preferred Stock and Series C Preferred Stock have no expiration date. F3 · derivative.expiration_date: Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one share of Class B Common Stock immediately prior to the closing of the IPO. Other than the aforementioned conversion, Series B Preferred Stock and Series C Preferred Stock have no expiration date. F2 · ownership.nature: The securities reported in this row are held directly held by GV 2017, L.P. (the "Partnership"). The general partner of the Partnership is GV 2017 GP, L.P. (the "GP"). The general partner of the GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole managing member of GV 2017 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole managing member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
October 18, 2021 Filed May 6, 2022 16:18 UTC	Gitlab Inc. GTLB · Entity 3663	ConversionSeries C Preferred Stock · Derivative	8,374,040	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-027590 · doc4.xml · derivative · entry 2 GV 2017 GP, L.L.C. · CIK 0001733338 · 10% owner GV 2017 GP, L.P. · CIK 0001733339 · 10% owner GV 2017, L.P. · CIK 0001733340 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2017, L.P. Disclosed balance after: 0 Underlying: Class B Common Stock · 8,374,040 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one share of Class B Common Stock immediately prior to the closing of the IPO. Other than the aforementioned conversion, Series B Preferred Stock and Series C Preferred Stock have no expiration date. F3 · price: Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one share of Class B Common Stock immediately prior to the closing of the IPO. Other than the aforementioned conversion, Series B Preferred Stock and Series C Preferred Stock have no expiration date. F3 · derivative.exercise_date: Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one share of Class B Common Stock immediately prior to the closing of the IPO. Other than the aforementioned conversion, Series B Preferred Stock and Series C Preferred Stock have no expiration date. F3 · derivative.expiration_date: Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one share of Class B Common Stock immediately prior to the closing of the IPO. Other than the aforementioned conversion, Series B Preferred Stock and Series C Preferred Stock have no expiration date. F2 · ownership.nature: The securities reported in this row are held directly held by GV 2017, L.P. (the "Partnership"). The general partner of the Partnership is GV 2017 GP, L.P. (the "GP"). The general partner of the GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole managing member of GV 2017 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole managing member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.